Biosensors Patents: Who Leads, Where the Gaps Are 2026
Biosensors patents: mapping the leaders, the filing trend and the open claim space
One leader, then a long tail. The top assignee holds 54 records while the ranked leaders' combined top 5 account for just 11.6% of all 1,944 records in scope. Publications ran from 92 in 2017 to 8 in 2026 (a partial year). The most recent complete comparison, 2021 to 2024, shows volume down 31%, from 84 to 58 records; treat 2025 and 2026 figures as still filling in rather than as evidence of a further decline.
- 1DIGITAL LUMENS HOLDING CO LLC2.8%
- 2MEDTRONIC INC2.7%
- 3SONY GROUP CORP2.1%
- 4GENTEX CORP2.1%
- 5ABBOTT DIAGNOSTICS SCARBOROUGH INC2.0%
See the full biosensors patent landscape analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about the biosensors patent landscape
Who are the leading patent holders in biosensors?
The assignee ranking covers 100 companies counted by record, with one clear leader holding 54 records ahead of a field that thins out gradually rather than dropping off sharply. The combined top 5 account for 11.6% of all 1,944 records in scope, and the top 10 for 20.1%, which means no single company or small group controls the technology. This is a fragmented field with room for new entrants to build a meaningful position without displacing an entrenched incumbent.
Is biosensor patent filing activity growing or slowing?
Filings peaked in 2017 at 92 records and have eased since, with the most recent complete comparison showing a 31% decline from 84 records in 2021 to 58 in 2024. Figures for 2025 and 2026 will continue to rise as publications catch up, because publication typically lags the actual filing date by around 18 months. So the honest read is a cooling trend through 2024, not a collapse, and the newest years should not be read as confirming further decline yet.
Which patent classes cover the most biosensor filings?
G01N (material analysis and testing) and A61B (diagnosis and surgery) are the two largest classes, each appearing in roughly 28-29% of the 1,944 records. G06F (digital data processing), A61N (electrotherapy), and C12Q (enzyme and DNA measurement) follow at meaningfully lower shares. Because a single record can carry multiple IPC classes, these percentages add up to well over 100% of the record total, and that overlap itself is informative: it shows how often a single filing covers both the sensing mechanism and its clinical application.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Biosensors Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.